- Viral RNA load in nasopharyngeal swabs up to 7 days post-treatment
- Disease progression up to 28 days, using the WHO scale
- Duration of symptoms

University of Michigan - Ann Arbor

Individuals were identified through the Epidemiological Surveillance Emergency Service of Catalonia (SUVEC), an electronic registry that is notified of all regional COVID-19 cases. 293 participants were eligible for the study (non-hospitalized individuals, <5 days since symptom onset) and randomly selected by a computer generator for either HCQ intervention or control arm. 136 were assigned HCQ and 157 assigned no antiviral treatment (not-placebo controlled). 800 mg of HCQ was administered on day 1, with an additional 400 mg/day for 6 days). Nasopharyngeal and serial oral swabs were collected on days 1, 3, and 7.

Methods from Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial

Mitjà,O., Corbacho-Monné, M., Ubals,M. et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial, Clinical Infectious Diseases, , ciaa1009, https://doi.org/10.1093/cid/ciaa1009

Learn Before

Related